Karyopharm Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Growth Amidst ...
KPTI Stock | USD 7.95 0.40 4.79% |
Under 67% of Karyopharm Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Karyopharm Therapeutics suggests that many traders are alarmed. Karyopharm Therapeutics' investing sentiment shows overall attitude of investors towards Karyopharm Therapeutics.
Karyopharm |
Total Revenue 38.8 million for Q3 2024, compared to 36 million for Q3 2023.Net US XPOVIO Revenue 29.5 million for Q3 2024, compared to 30.2 million for Q
Read at gurufocus.com
![]() |
Karyopharm Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Karyopharm Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Karyopharm Therapeutics Maximum Pain Price Across May 16th 2025 Option Contracts
Karyopharm Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Karyopharm Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Karyopharm Therapeutics' options.
Karyopharm Therapeutics Fundamental Analysis
We analyze Karyopharm Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karyopharm Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karyopharm Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Karyopharm Therapeutics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Karyopharm Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Karyopharm Therapeutics stock to make a market-neutral strategy. Peer analysis of Karyopharm Therapeutics could also be used in its relative valuation, which is a method of valuing Karyopharm Therapeutics by comparing valuation metrics with similar companies.
Peers
Karyopharm Therapeutics Related Equities
XFOR | X4 Pharmaceuticals | 8.11 | ||||
BLUE | Bluebird Bio | 7.37 | ||||
LYRA | Lyra Therapeutics | 5.00 | ||||
MRSN | Mersana Therapeutics | 4.00 | ||||
AGIO | Agios Pharm | 3.49 | ||||
GOSS | Gossamer Bio | 3.36 | ||||
KRON | Kronos Bio | 2.08 | ||||
HOOK | Hookipa Pharma | 2.00 | ||||
ABOS | Acumen Pharmaceuticals | 1.59 | ||||
GLUE | Monte Rosa | 0.92 | ||||
REPL | Replimune | 0.32 | ||||
NVCT | Nuvectis Pharma | 0.30 | ||||
NUVB | Nuvation Bio | 0.51 | ||||
ASMB | Assembly Biosciences | 0.69 | ||||
CTMX | CytomX Therapeutics | 1.45 | ||||
RLYB | Rallybio Corp | 2.70 | ||||
MREO | Mereo BioPharma | 2.78 | ||||
PMVP | Pmv Pharmaceuticals | 2.84 | ||||
GBIO | Generation Bio | 3.57 |
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |